- ...a new drug candidate that addresses the basic defect in CF, VX 770, entered Phase 2 clinical trials. This oral drug candidate, which aims to restore the function of the defective CFTR protein, has many steps to go before drug approval, but it is an exciting milestone in our ongoing efforts to advance drug development.
VX 770 looks interesting. I realize that it is several years from FDA approval but if the defective CFTR protein can be repaired - wow. The potential for those living with CF is huge.
No comments:
Post a Comment